Clinical Trial

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 14, 2023 (before its estimated January 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of perioperative Disitamab Vedotin plus Toripalimab and XELOX versus Disitamab Vedotin plus Toripalimab versus XELOX in subjects with HER2-expressing resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-23.
Status change: Not Yet Recruiting → Recruiting 2023-12-12
Trial Details
NCT Number NCT06155383
Lead Sponsor RemeGen Co., Ltd.
Conditions Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Enrollment 90 participants
Start Date 2023-11-27
Primary Completion 2025-01-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-12-14